Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?

July 6, 2024

Wockhardt’s Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk’s Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.

More To Explore

Warren Buffett’s $11 billion oil bet is down 21% from 2025 peak. Will this be his oil regret 2.0?

One of Warren Buffett’s largest public equity investments is now deep in the red. Occidental Petroleum, in which Berkshire Hathaway holds a 28.2% stake, has

May 11, 2025

ETMarkets Smart Talk: Logistics, retail, green energy set to soar under India-UK FTA, says Charles Russell Speechlys’ Kim Lalli

As the long-awaited India-UK Free Trade Agreement edges closer to finalisation, optimism is running high across key industries. Kim Lalli, Partner at international law firm

May 11, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003